ClinicalTrials.gg
CompletedNCT00105027SCOREUpdated Jul 2, 2018Results posted

The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study

A Phase 3 interventional study of Standard Care and intravitreal triamcinolone injection in Macular Edema, Cystoid and Retinal Vein Occlusion, sponsored by The Emmes Company, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-02.

Sponsored by The Emmes Company, LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
682
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing triamcinolone in Macular Edema — 1 open to participants now, 1 under way, none of them phase 3. Triamcinolone · Macular Edema.

Enrollment
3rd of 35
682 · median 71
Started
2004
the only one that year
Phase 3
15 of 38
none open now
Registered
3rd of 38
by date

Among the 38 studies testing triamcinolone in Macular Edema, this one is the 3rd largest by enrollment of the 35 interventional ones that give a count, is the only one that started in 2004, is one of 15 in phase 3, and was the 3rd registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 38 studies testing triamcinolone in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About triamcinolone

Triamcinolone: first FDA approval 1957 (ARISTOCORT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing triamcinolone in Macular Edema, or all of them as a file.
02

Study summary

The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).

Read the detailed description

Macular edema is a major cause of vision loss in patients with CRVO and BRVO. Both CRVO and BRVO are common retinal problems and are caused by a blockage in one of the large retinal veins (central retinal vein occlusion - CRVO) or smaller retinal veins (branch retinal vein occlusion - BRVO). Currently, there is no effective treatment for macular edema associated with CRVO and standard care treatment is observation. Grid laser photocoagulation may be effective for some patients for macular edema associated with BRVO, but many patients derive limited benefit from this treatment. Therefore, the development of new treatment modalities for macular edema caused by these two conditions is an important research goal.

Over the last several years, many patients with macular edema from CRVO and BRVO have been treated with an injection of a type of steroid called triamcinolone directly into the eye. This type of injection is called an intravitreal injection. The triamcinolone preparation commonly injected into the eye is Kenalog and is FDA-approved only for use in muscles and joints. The SCORE Study will use a formulation of triamcinolone made specifically for the eye.

The SCORE Study is a multicenter, randomized, Phase III trial to compare the effectiveness and safety of standard care versus triamcinolone injection(s) for the treatment of macular edema associated with CRVO and BRVO. In each of the two disease areas, 630 participants will be randomized (similar to a flip of a coin) in a 1:1:1 ratio to one of three groups: standard care, intravitreal triamcinolone 4 mg, or intravitreal triamcinolone 1 mg. After randomization, participants will be examined every 4 months through 3 years to collect ophthalmic information, including visual acuity, intraocular pressure, optical coherence tomography, and fundus photography . Fluorescein angiography will be performed at 4, 12 and 24 months. Repeat intravitreal injections of triamcinolone and repeat laser treatment will be provided as clinically indicated based on protocol-specific guidelines.

The primary outcome is improvement by 15 or more letters from baseline in best-corrected ETDRS visual acuity score at the 12-month visit. Secondary outcomes include changes from baseline in best-corrected ETDRS visual acuity score, changes in retinal thickness as assessed by stereoscopic color fundus photography and optical coherence tomography, and adverse ocular outcomes.

03

Conditions studied

  • Macular Edema, Cystoid
  • Retinal Vein Occlusion

Keywords

  • macular edema
  • central retinal vein occlusion (CRVO)
  • branch retinal vein occlusion (BRVO)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Participants with macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
  • Individuals, 18 years of age or older, willing to provide consent may be eligible for the SCORE Study.

Exclusion Criteria: refer to SCORE Study website at https://web.emmes.com/study/score/ for listing.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
682 participants (actual)

Study arms

  • Active comparator
    CRVO Observation

    Other: Standard Care

  • Active comparator
    CRVO 1 mg dose triamcinolone acetonide

    Drug: intravitreal triamcinolone injection

  • Active comparator
    CRVO 4 mg dose triamcinolone acetonide

    Drug: intravitreal triamcinolone injection

  • Active comparator
    BRVO standard care

    Other: Standard Care

  • Active comparator
    BRVO 1 mg dose triamcinolone acetonide

    Drug: intravitreal triamcinolone injection

  • Active comparator
    BRVO 4 mg dose triamcinolone acetonide

    Drug: intravitreal triamcinolone injection

Interventions

06

What researchers measure

Primary outcomes

  1. The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit

    Visual acuity testing was done using electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity testing at 3 meters using the Electronic Visual Acuity Tester by a SCORE certified technician. A masked visual acuity examiner with no knowledge of treatment assignments performed visual acuity testing at the 4-month, 12-month, 24-month and 36-month visits. An E-ETDRS visual acuity score of 85 is approximately 20/20, and a score of 20 letters is approximately 20/400. A visual acuity letter score change of 15 is about three lines on a vision chart.

    Time frame: Change from baseline to 12 months

Secondary outcomes

  1. Changes From Baseline in Best-corrected ETDRS Visual Acuity Score

    Time frame: 12 months

  2. Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography

    Time frame: 12 months

  3. Adverse Ocular Outcomes

    Time frame: 12 months

07

Results

Posted Jan 19, 2011

Participant flow

Between November 8, 2004, and February 29, 2008, 271 patients with central retinal vein occlusion (CRVO) were enrolled from 66 clinical sites and 411 patients with branch retinal vein occlusion (BRVO) were enrolled from 75 clinical sites across the United States. Participant flow data are reported for the primary outcome measure (12 months).

Participant flow — Overall Study
MilestoneCRVO ObservationCRVO 1 mg Dose Triamcinolone AcetonideCRVO 4 mg Dose Triamcinolone AcetonideBRVO Standard CareBRVO 1 mg Dose Triamcinolone AcetonideBRVO 4 mg Dose Triamcinolone Acetonide
Started889291137136138
Completed738382121121125
Not completed1599161513

Outcome measures

PrimaryThe Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit

Visual acuity testing was done using electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity testing at 3 meters using the Electronic Visual Acuity Tester by a SCORE certified technician. A masked visual acuity examiner with no knowledge of treatment assignments performed visual acuity testing at the 4-month, 12-month, 24-month and 36-month visits. An E-ETDRS visual acuity score of 85 is approximately 20/20, and a score of 20 letters is approximately 20/400. A visual acuity letter score change of 15 is about three lines on a vision chart.

Time frame:
Change from baseline to 12 months
Reported as:
Number · Participants
The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit
ParticipantsCRVO ObservationCRVO 1 mg Dose Triamcinolone AcetonideCRVO 4 mg Dose Triamcinolone AcetonideBRVO Standard CareBRVO 1 mg Dose Triamcinolone AcetonideBRVO 4 mg Dose Triamcinolone Acetonide
The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit522 (-6.4 to 4.1)21 (-6.3 to 4.0)35 (1.1 to 7.3)31 (2.8 to 8.6)34 (0.9 to 7.2)
SecondaryChanges From Baseline in Best-corrected ETDRS Visual Acuity Score
Time frame:
12 months
Reported as:
Mean · letters read
Changes From Baseline in Best-corrected ETDRS Visual Acuity Score
letters readCRVO ObservationCRVO 1 mg Dose Triamcinolone AcetonideCRVO 4 mg Dose Triamcinolone AcetonideBRVO Standard CareBRVO 1 mg Dose Triamcinolone AcetonideBRVO 4 mg Dose Triamcinolone Acetonide
Changes From Baseline in Best-corrected ETDRS Visual Acuity Score-12.1 (-17.1 to -7.1)-1.2 (-6.4 to 4.1)-1.2 (-6.3 to 4.0)4.2 (1.1 to 7.3)5.7 (2.8 to 8.6)4.0 (0.9 to 7.2)
SecondaryChanges in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography
Time frame:
12 months
Reported as:
Median · um
Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography
umCRVO ObservationCRVO 1 mg Dose Triamcinolone AcetonideCRVO 4 mg Dose Triamcinolone AcetonideBRVO Standard CareBRVO 1 mg Dose Triamcinolone AcetonideBRVO 4 mg Dose Triamcinolone Acetonide
Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography-277 (-418 to -40)-196 (-390 to -62)-261 (-407 to -79)-224 (-411 to -67)-149 (-279 to -18)-170 (-304 to -63)
SecondaryAdverse Ocular Outcomes
Time frame:
12 months
Reported as:
Number · events
Adverse Ocular Outcomes
eventsCRVO ObservationCRVO 1 mg Dose Triamcinolone AcetonideCRVO 4 mg Dose Triamcinolone AcetonideBRVO Standard CareBRVO 1 mg Dose Triamcinolone AcetonideBRVO 4 mg Dose Triamcinolone Acetonide
Initiation of IOP-lowering medications7183231157
IOP > 35 mm HG1581214
IOP > 10 mm HG above baseline2152411250
Laser peripheral iridotomy001001
Trabeculectomy000000
Tube shunt020000
Cataract: lens opacity onset or progression122025152738
Cataract surgery004304
Infectious endophthalmitis000001
Noninfectious endophthalmitis000000
Retinal detachment000110
Iris neovascularization294112
Retinal neovascularization422513
Vitreous hemorrhage440213
YAG capsulotomy100101
Sector or panretinal photocagulation593514
Pars plana vitrectomy120101

Adverse events

Collected over Three years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CRVO Observation0/88 (0%)32/88 (36.4%)76/88 (86.4%)
CRVO 1 mg Dose Triamcinolone Acetonide1/92 (1.1%)37/92 (40.2%)87/92 (94.6%)
CRVO 4 mg Dose Triamcinolone Acetonide2/91 (2.2%)53/91 (58.2%)89/91 (97.8%)
BRVO Standard Care3/137 (2.2%)47/137 (34.3%)118/137 (86.1%)
BRVO 1 mg Dose Triamcinolone Acetonide2/136 (1.5%)49/136 (36%)132/136 (97.1%)
BRVO 4 mg Dose Triamcinolone Acetonide2/138 (1.4%)79/138 (57.2%)133/138 (96.4%)
Most frequent serious events
Showing 10 of 209
Most frequent serious events
EventCRVO ObservationCRVO 1 mg Dose Triamcinolone AcetonideCRVO 4 mg Dose Triamcinolone AcetonideBRVO Standard CareBRVO 1 mg Dose Triamcinolone AcetonideBRVO 4 mg Dose Triamcinolone Acetonide
CataractEye disorders5/889/9228/9112/13716/13640/138
Cataract subcapsularEye disorders0/880/921/911/1371/13612/138
GlaucomaEye disorders1/885/923/910/1370/1362/138
Cerebrovascular accidentNervous system disorders2/880/924/913/1371/1363/138
Angina unstableCardiac disorders3/880/920/910/1370/1360/138
Intraocular pressure increasedInvestigations3/882/923/910/1370/1364/138
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/880/923/910/1370/1360/138
SyncopeNervous system disorders0/880/923/911/1371/1360/138
PneumoniaInfections and infestations2/882/920/911/1374/1362/138
CellulitisInfections and infestations2/880/920/910/1372/1361/138
Most frequent other events
Showing 10 of 33
Most frequent other events
EventCRVO ObservationCRVO 1 mg Dose Triamcinolone AcetonideCRVO 4 mg Dose Triamcinolone AcetonideBRVO Standard CareBRVO 1 mg Dose Triamcinolone AcetonideBRVO 4 mg Dose Triamcinolone Acetonide
Foreign body in eyeInjury, poisoning and procedural complications5/8831/9222/914/13767/13631/138
Intraocular pressure increasedInvestigations8/8820/9242/917/13719/13664/138
MyodesopsiaEye disorders8/8832/9234/9117/13759/13645/138
Conjunctival haemorrhageEye disorders3/8834/9230/919/13754/13654/138
Eye painEye disorders6/8815/9218/919/13723/13618/138
Vitreous detachmentEye disorders8/8816/9210/9115/13721/13612/138
CataractEye disorders10/889/9214/9115/13719/13621/138
Cataract subcapsularEye disorders3/888/9212/912/13713/13616/138
Visual acuity reducedEye disorders10/8812/9210/916/13711/13613/138
Eye irritationEye disorders2/8811/929/916/13717/1368/138

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CRVO ObservationCRVO 1 mg Dose Triamcinolone AcetonideCRVO 4 mg Dose Triamcinolone AcetonideBRVO Standard CareBRVO 1 mg Dose Triamcinolone AcetonideBRVO 4 mg Dose Triamcinolone AcetonideTotal
<=18 years0000000
Between 18 and 65 years253534625455265
>=65 years635757758283417
Age, Continuous
Age, Continuous(years)CRVO ObservationCRVO 1 mg Dose Triamcinolone AcetonideCRVO 4 mg Dose Triamcinolone AcetonideBRVO Standard CareBRVO 1 mg Dose Triamcinolone AcetonideBRVO 4 mg Dose Triamcinolone AcetonideTotal
Mean69.2 ± 12.867.4 ± 12.467.5 ± 12.066.9 ± 11.567.2 ± 11.568.1 ± 10.667.7 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)CRVO ObservationCRVO 1 mg Dose Triamcinolone AcetonideCRVO 4 mg Dose Triamcinolone AcetonideBRVO Standard CareBRVO 1 mg Dose Triamcinolone AcetonideBRVO 4 mg Dose Triamcinolone AcetonideTotal
Female404340716863325
Male484951666875357
Region of Enrollment
Region of Enrollment(participants)CRVO ObservationCRVO 1 mg Dose Triamcinolone AcetonideCRVO 4 mg Dose Triamcinolone AcetonideBRVO Standard CareBRVO 1 mg Dose Triamcinolone AcetonideBRVO 4 mg Dose Triamcinolone AcetonideTotal
United States889291137136138682
08

Study locations

1 site
  • University of Wisconsin
    Madison, Wisconsin 53711, United States
09

References and documents

Publications

  • Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol. 2007 Sep;144(3):454-6. doi: 10.1016/j.ajo.2007.04.011. PubMed 17765429 ↗
  • Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M; SCORE Study Investigator Group. SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology. 2009 Mar;116(3):504-12. doi: 10.1016/j.ophtha.2008.10.017. Epub 2009 Jan 22. PubMed 19167078 ↗
  • Scott IU, Blodi BA, Ip MS, Vanveldhuisen PC, Oden NL, Chan CK, Gonzalez V; SCORE Study Investigator Group. SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type. Ophthalmology. 2009 Apr;116(4):756-61. doi: 10.1016/j.ophtha.2008.11.015. PubMed 19344824 ↗
  • Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Figueroa M, Antoszyk A, Elman M; SCORE Study Investigator Group. SCORE Study report 3: study design and baseline characteristics. Ophthalmology. 2009 Sep;116(9):1770-1777.e1. doi: 10.1016/j.ophtha.2009.03.022. Epub 2009 Jul 19. PubMed 19619896 ↗
  • Domalpally A, Blodi BA, Scott IU, Ip MS, Oden NL, Lauer AK, VanVeldhuisen PC; SCORE Study Investigator Group. The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of optical coherence tomograms: SCORE study report 4. Arch Ophthalmol. 2009 Nov;127(11):1461-7. doi: 10.1001/archophthalmol.2009.277. PubMed 19901211 ↗
  • Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN; SCORE Study Investigator Group. SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. Am J Ophthalmol. 2009 Nov;148(5):725-732.e7. doi: 10.1016/j.ajo.2009.06.004. Epub 2009 Aug 11. PubMed 19674727 ↗
  • Oden N, Vanveldhuisen PC, Scott IU, Ip MS; the SCORE Study Investigator Group. SCORE Study Report 8: Closed Tests for All Pair-Wise Comparisons of Means. Drug Inf J. 2010 Jul 1;44(4):405-420. doi: 10.1177/009286151004400405. PubMed 21660119 ↗
  • Blodi BA, Domalpally A, Scott IU, Ip MS, Oden NL, Elledge J, Warren K, Altaweel MM, Kim JE, Van Veldhuisen PC; SCORE Study Research Group. Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study system for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE Study Report 9. Arch Ophthalmol. 2010 Sep;128(9):1140-5. doi: 10.1001/archophthalmol.2010.193. PubMed 20837797 ↗
  • Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Hartnett ME, Cohen G; Standard Care versus COrticosteroid for REtinal Vein Occlusion Study Investigator Group. Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10. Ophthalmology. 2011 Feb;118(2):345-52. doi: 10.1016/j.ophtha.2010.06.034. PubMed 20926135 ↗
  • Chan CK, Ip MS, Vanveldhuisen PC, Oden NL, Scott IU, Tolentino MJ, Blodi BA; SCORE Study Investigator Group. SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion. Ophthalmology. 2011 Jul;118(7):1364-72. doi: 10.1016/j.ophtha.2010.11.020. Epub 2011 Mar 26. PubMed 21440942 ↗
  • Domalpally A, Peng Q, Danis R, Blodi B, Scott IU, Ip M; SCORE Study Research Group. Association of outer retinal layer morphology with visual acuity in patients with retinal vein occlusion: SCORE Study Report 13. Eye (Lond). 2012 Jul;26(7):919-24. doi: 10.1038/eye.2012.59. Epub 2012 Apr 27. PubMed 22538214 ↗
  • Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009 Sep;127(9):1101-14. doi: 10.1001/archophthalmol.2009.234. Erratum In: Arch Ophthalmol. 2009 Dec;127(12):1648. PubMed 19752419 ↗
  • Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009 Sep;127(9):1115-28. doi: 10.1001/archophthalmol.2009.233. Erratum In: Arch Ophthalmol. 2009 Dec;127(12):1655. PubMed 19752420 ↗
  • Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE Study Investigator Group. Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15. JAMA Ophthalmol. 2015 Sep;133(9):1022-9. doi: 10.1001/jamaophthalmol.2015.1823. PubMed 26086920 ↗
  • Scott IU, Vanveldhuisen PC, Oden NL, Ip MS, Domalpally A, Doft BH, Elman MJ, Blodi BA; SCORE Study Investigator Group. Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14. Arch Ophthalmol. 2012 Dec;130(12):1517-24. doi: 10.1001/archophthalmol.2012.2728. PubMed 23229691 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data sets will be provided to qualified investigators under a Data Use Agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: to be set forth in data use agreement

Access criteria: qualified investigators

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2005
First posted
Mar 4, 2005
Start
Oct 2004
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Jan 19, 2011
Last update
Jul 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00105027
Lead sponsor
The Emmes Company, LLC
Responsible party
Sponsor
First posted
Mar 4, 2005
Start date
Oct 2004
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Jan 19, 2011
Last update
Jul 2, 2018

Study contacts

Michael S. Ip, M.D.
study chair · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone

Start the discussion